Decipher® delivers unique, personalized and actionable results to inform treatment decisions after biopsy and surgery1, 2, 3

  • Decipher analyzes the expression of 22 biomarkers across the genome to generate a robust genomic risk score

Decipher Biopsy

Decipher Biopsy reports a score to predict the likelihood of metastasis, high-grade disease and prostate cancer specific death for men diagnosed with localized disease.

Easy to interpret

Decipher Biopsy is based on patients’ personal tumor-based genomics, to help determine who:

  • May be suitable candidates for active surveillance
  • May be treated with local therapy alone
  • May benefit from intensification of multi-modal therapy
Decipher Classification Patient Management Recommendations
Genomic Low Risk Favorable prognosis – may be suitable candidate for active surveillance and may have excellent outcomes when treated with local therapy alone
Genomic High Risk Unfavorable prognosis – may not be suitable candidate for active surveillance and may benefit from intensification with multi-modal therapy

Click here to download the Decipher Biopsy Sample Test report

Low Risk Biopsy


Decipher Post-Op

Decipher Post-Op reports a score to predict the likelihood of metastasis and prostate cancer specific death for men after prostatectomy surgery.

Easy to interpret

Patients are identified as High, Average or Low risk based on their predicted probability of developing metastasis and prostate cancer specific death.

Decipher Classification Treatment recommended post-surgery Treatment recommended post-surgery after PSA rise or biochemical recurrence (BCR)
Genomic Low Risk Observation with PSA monitoring until detectable PSA rise, if any/ever

  • 98.5% 5 year metastasis-free survival
  • 95% 10 year prostate cancer-specific survival
Radiation alone is sufficient. Concurrent hormone therapy may be avoided.
Genomic High Risk 80% reduction in metastasis risk in Decipher high-risk patients who receive adjuvant or early radiation Radiation alone is insufficient. Intensification of treatment may be needed.

Decipher tells you something new for 80% of patients tested

In clinical studies, Decipher reclassified 80% of clinically high-risk patients after surgery to lower (60%) or higher (20%) risk categories.
Summary of key data for Decipher

Click here to download the Decipher Post-op Sample Test report

Low Risk Post-Op